Cullen/Frost Bankers, Inc. posted a net income of $178.5 million for Q3 2026, up from $172.7 million in Q3 2025, driven by a 9% loan growth and 3.6% deposit increase. The bank's net interest income rose 5.8% year-over-year, supported by expanding customer base and wealth management growth. The board declared a Q4 cash dividend of $1.03 per common share, payable in December 2026. The bank remains well-capitalized with strong asset quality and plans to continue growth amid Texas's economic expansion.
Cullen/Frost Bankers reported its third quarter results, providing context for financial market activity. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 29, 2026 19:11 WIB: out of 142 priced US Financial stocks, 96 rose and 42 fell. Notable movers include WULF at USD 12.84 with a 1-day change of -4.32%, BBVA at USD 23.95 with 100% buy order activity, and RIOT at USD 13.85 with a 1-day change of -4.15%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
